<ul>
<li>三家醫療巨頭剛剛提高了股息——誰支付得最多</li>
</ul>
<p>根據 MarketBeat 的股票篩選工具，Eli Lilly and Company、Pfizer、Bristol Myers Squibb、AbbVie、Gemini Therapeutics、Novo Nordisk A/S 和 Cytokinetics 是今天值得關注的七隻製藥股票。製藥股票是指那些研究、開發、生產和銷售處方藥、疫苗及相關醫療產品的公司的公開交易股票。對於投資者而言，這些股票受臨牀試驗結果、監管批准、專利生命週期和醫療政策的驅動，這可能創造出可觀的增長潛力，但也伴隨着高波動性和風險。這些公司在過去幾天內的製藥股票交易量最高。</p>
<p>獲取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
<h2>Eli Lilly and Company (LLY)</h2>
<p>Eli Lilly and Company 在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素 lispro、胰島素 lispro 原料、胰島素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；Zepbound 用於肥胖。</p>
<ul>
<li>Pfizer 加大對減肥藥物的投資</li>
</ul>
<p>閲讀我們關於 LLY 的最新研究報告</p>
<h2>Pfizer (PFE)</h2>
<p>Pfizer Inc.在美國、歐洲及國際上發現、開發、製造、營銷、分銷和銷售生物製藥產品。該公司在多個治療領域提供藥物和疫苗，包括心血管代謝、偏頭痛和女性健康，品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；針對未滿足醫療需求的傳染病，品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的預防和治療，以及潛在的未來 mRNA 和抗病毒產品，品牌包括 Comirnaty 和 Paxlovid。</p>
<ul>
<li>黃金交叉警報：三隻具有重大上漲潛力的股票</li>
</ul>
<p>閲讀我們關於 PFE 的最新研究報告</p>
<h2>Bristol Myers Squibb (BMY)</h2>
<p>Bristol-Myers Squibb Company 在全球範圍內發現、開發、許可、製造、營銷、分銷和銷售生物製藥產品。它提供用於血液學、腫瘤學、心血管、免疫學、纖維化和神經科學疾病的產品。該公司的產品包括 Eliquis，用於降低非瓣膜性心房顫動患者中風/全身栓塞的風險，以及治療深靜脈血栓/肺栓塞；Opdivo 用於多種抗癌適應症，包括膀胱癌、血液癌、結直腸癌、頭頸癌、腎細胞癌、肝細胞癌、肺癌、黑色素瘤、胸膜間皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用於多發性骨髓瘤；Orencia 用於活動性類風濕關節炎和銀屑病關節炎；Sprycel 用於治療費城染色體陽性慢性髓性白血病。</p>
<p>閲讀我們關於 BMY 的最新研究報告</p>
<h2>AbbVie (ABBV)</h2>
<p>AbbVie Inc.在全球範圍內發現、開發、製造和銷售藥物。該公司提供 Humira，一種用於自身免疫性和腸道貝赫切特病及膿皮病壞死的注射劑；Skyrizi 用於治療中度至重度斑塊型銀屑病、銀屑病性疾病和克羅恩病；Rinvoq 用於治療類風濕關節炎和銀屑病關節炎、強直性脊柱炎、特應性皮炎、軸性脊柱關節炎、潰瘍性結腸炎和克羅恩病；Imbruvica 用於治療成人血癌；Epkinly 用於治療淋巴瘤；Elahere 用於治療癌症；Venclexta/Venclyxto 用於治療血癌。</p>
<p>閲讀我們關於 ABBV 的最新研究報告</p>
<h2>Gemini Therapeutics (GMTX)</h2>
<p>Gemini Therapeutics, Inc.是一家臨牀階段的精準醫學公司，致力於開發用於治療基因定義的年齡相關性黃斑變性（AMD）的各種治療化合物。其主要候選藥物是 GEM103，一種重組人補體因子 H 蛋白，用於治療乾性 AMD 患者。</p>
<p>閲讀我們關於 GMTX 的最新研究報告</p>
<h2>Novo Nordisk A/S (NVO)</h2>
<p>Novo Nordisk A/S 及其子公司從事藥品的研究與開發、製造和分銷，覆蓋歐洲、中東、非洲、中國大陸、香港、台灣、北美及國際市場。它分為兩個部門，糖尿病和肥胖護理，以及罕見疾病。</p>
<p>閲讀我們關於 NVO 的最新研究報告</p>
<h2>Cytokinetics (CYTK)</h2>
<p>Cytokinetics, Incorporated 是一家晚期生物製藥公司，專注於發現、開發和商業化肌肉激活劑和抑制劑，作為潛在的治療方案。該公司開發的小分子藥物候選者主要旨在影響肌肉功能和收縮性。</p>
<p>閲讀我們關於 CYTK 的最新研究報告</p>
<h2>進一步閲讀</h2>
<ul>
<li>MarketBeat 在 2025 年 12 月的五大股票推薦</li>
<li>RKLB、ASTS、TDG：內部人士正在出售這三隻航天股票</li>
<li>Instacart 被監控定價...但投資者並不在意</li>
<li>Broadcom 剛剛提高了股息——但這並不是唯一一個發出強勁信號的公司</li>
<li>亞馬遜現在的配送推動可能提升其 2026 年展望</li>
<li>2026 年值得關注的五隻小型股，投資者正在從大型科技股中撤出</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Eli Lilly and Company 嗎？</h2>
<p>在考慮 Eli Lilly and Company 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Eli Lilly and Company 並不在名單上。</p>
<p>雖然禮來目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

百時美施貴寶

禮來

<p>MarketBeat 的股票篩選工具突出了七隻值得關注的製藥股票：禮來、輝瑞、百時美施貴寶、艾伯維、雙子治療、諾和諾德和細胞動力學。這些股票受到臨牀試驗結果、監管批准和醫療政策的推動，具有增長潛力，但也伴隨高波動性。禮來、輝瑞和百時美施貴寶最近提高了股息，顯示出其強勁的表現。投資者應考慮這些股票的潛在上漲空間</p>

<ul>
<li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li>
</ul>
<div class="lb-trans"><ul>
<li>三家醫療巨頭剛剛提高了股息——誰支付得最多</li>
</ul>
</div><p>Eli Lilly and Company, Pfizer, Bristol Myers Squibb, AbbVie, Gemini Therapeutics, Novo Nordisk A/S, and Cytokinetics are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are publicly traded shares of companies that research, develop, manufacture, and sell prescription drugs, vaccines, and related medical products. For investors, these stocks are driven by clinical-trial results, regulatory approvals, patent lifecycles, and healthcare policy, which can create substantial growth potential but also high volatility and risk. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.</p>
<div class="lb-trans"><p>根據 MarketBeat 的股票篩選工具，Eli Lilly and Company、Pfizer、Bristol Myers Squibb、AbbVie、Gemini Therapeutics、Novo Nordisk A/S 和 Cytokinetics 是今天值得關注的七隻製藥股票。製藥股票是指那些研究、開發、生產和銷售處方藥、疫苗及相關醫療產品的公司的公開交易股票。對於投資者而言，這些股票受臨牀試驗結果、監管批准、專利生命週期和醫療政策的驅動，這可能創造出可觀的增長潛力，但也伴隨着高波動性和風險。這些公司在過去幾天內的製藥股票交易量最高。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
</div><h2>Eli Lilly and Company (LLY)</h2>
<div class="lb-trans"><h2>Eli Lilly and Company (LLY)</h2>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>Eli Lilly and Company 在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素 lispro、胰島素 lispro 原料、胰島素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；Zepbound 用於肥胖。</p>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>Pfizer 加大對減肥藥物的投資</li>
</ul>
</div><p>Read Our Latest Research Report on LLY</p>
<div class="lb-trans"><p>閲讀我們關於 LLY 的最新研究報告</p>
</div><h2>Pfizer (PFE)</h2>
<div class="lb-trans"><h2>Pfizer (PFE)</h2>
</div><p>Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p>
<div class="lb-trans"><p>Pfizer Inc.在美國、歐洲及國際上發現、開發、製造、營銷、分銷和銷售生物製藥產品。該公司在多個治療領域提供藥物和疫苗，包括心血管代謝、偏頭痛和女性健康，品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；針對未滿足醫療需求的傳染病，品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的預防和治療，以及潛在的未來 mRNA 和抗病毒產品，品牌包括 Comirnaty 和 Paxlovid。</p>
</div><ul>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>黃金交叉警報：三隻具有重大上漲潛力的股票</li>
</ul>
</div><p>Read Our Latest Research Report on PFE</p>
<div class="lb-trans"><p>閲讀我們關於 PFE 的最新研究報告</p>
</div><h2>Bristol Myers Squibb (BMY)</h2>
<div class="lb-trans"><h2>Bristol Myers Squibb (BMY)</h2>
</div><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p>
<div class="lb-trans"><p>Bristol-Myers Squibb Company 在全球範圍內發現、開發、許可、製造、營銷、分銷和銷售生物製藥產品。它提供用於血液學、腫瘤學、心血管、免疫學、纖維化和神經科學疾病的產品。該公司的產品包括 Eliquis，用於降低非瓣膜性心房顫動患者中風/全身栓塞的風險，以及治療深靜脈血栓/肺栓塞；Opdivo 用於多種抗癌適應症，包括膀胱癌、血液癌、結直腸癌、頭頸癌、腎細胞癌、肝細胞癌、肺癌、黑色素瘤、胸膜間皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用於多發性骨髓瘤；Orencia 用於活動性類風濕關節炎和銀屑病關節炎；Sprycel 用於治療費城染色體陽性慢性髓性白血病。</p>
</div><p>Read Our Latest Research Report on BMY</p>
<div class="lb-trans"><p>閲讀我們關於 BMY 的最新研究報告</p>
</div><h2>AbbVie (ABBV)</h2>
<div class="lb-trans"><h2>AbbVie (ABBV)</h2>
</div><p>AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>AbbVie Inc.在全球範圍內發現、開發、製造和銷售藥物。該公司提供 Humira，一種用於自身免疫性和腸道貝赫切特病及膿皮病壞死的注射劑；Skyrizi 用於治療中度至重度斑塊型銀屑病、銀屑病性疾病和克羅恩病；Rinvoq 用於治療類風濕關節炎和銀屑病關節炎、強直性脊柱炎、特應性皮炎、軸性脊柱關節炎、潰瘍性結腸炎和克羅恩病；Imbruvica 用於治療成人血癌；Epkinly 用於治療淋巴瘤；Elahere 用於治療癌症；Venclexta/Venclyxto 用於治療血癌。</p>
</div><p>Read Our Latest Research Report on ABBV</p>
<div class="lb-trans"><p>閲讀我們關於 ABBV 的最新研究報告</p>
</div><h2>Gemini Therapeutics (GMTX)</h2>
<div class="lb-trans"><h2>Gemini Therapeutics (GMTX)</h2>
</div><p>Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.</p>
<div class="lb-trans"><p>Gemini Therapeutics, Inc.是一家臨牀階段的精準醫學公司，致力於開發用於治療基因定義的年齡相關性黃斑變性（AMD）的各種治療化合物。其主要候選藥物是 GEM103，一種重組人補體因子 H 蛋白，用於治療乾性 AMD 患者。</p>
</div><p>Read Our Latest Research Report on GMTX</p>
<div class="lb-trans"><p>閲讀我們關於 GMTX 的最新研究報告</p>
</div><h2>Novo Nordisk A/S (NVO)</h2>
<div class="lb-trans"><h2>Novo Nordisk A/S (NVO)</h2>
</div><p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p>
<div class="lb-trans"><p>Novo Nordisk A/S 及其子公司從事藥品的研究與開發、製造和分銷，覆蓋歐洲、中東、非洲、中國大陸、香港、台灣、北美及國際市場。它分為兩個部門，糖尿病和肥胖護理，以及罕見疾病。</p>
</div><p>Read Our Latest Research Report on NVO</p>
<div class="lb-trans"><p>閲讀我們關於 NVO 的最新研究報告</p>
</div><h2>Cytokinetics (CYTK)</h2>
<div class="lb-trans"><h2>Cytokinetics (CYTK)</h2>
</div><p>Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.</p>
<div class="lb-trans"><p>Cytokinetics, Incorporated 是一家晚期生物製藥公司，專注於發現、開發和商業化肌肉激活劑和抑制劑，作為潛在的治療方案。該公司開發的小分子藥物候選者主要旨在影響肌肉功能和收縮性。</p>
</div><p>Read Our Latest Research Report on CYTK</p>
<div class="lb-trans"><p>閲讀我們關於 CYTK 的最新研究報告</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>MarketBeat's Top Five Stocks to Own in December 2025</li>
<li>RKLB, ASTS, TDG: Insiders are Selling These 3 Space Stocks</li>
<li>Instacart Got Caught Surveillance Pricing... But Investors Didn't Care</li>
<li>Broadcom Just Raised Its Dividend—But It’s Not the Only One Signaling Strength</li>
<li>Amazon Now Delivery Push Could Boost Its 2026 Outlook</li>
<li>5 Small-Cap Stocks to Watch in 2026 as Investors Rotate Out of Big Tech</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 在 2025 年 12 月的五大股票推薦</li>
<li>RKLB、ASTS、TDG：內部人士正在出售這三隻航天股票</li>
<li>Instacart 被監控定價...但投資者並不在意</li>
<li>Broadcom 剛剛提高了股息——但這並不是唯一一個發出強勁信號的公司</li>
<li>亞馬遜現在的配送推動可能提升其 2026 年展望</li>
<li>2026 年值得關注的五隻小型股，投資者正在從大型科技股中撤出</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Eli Lilly and Company 嗎？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Eli Lilly and Company 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Eli Lilly and Company 並不在名單上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然禮來目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

12 月 22 日值得關注的頂級製藥股票